Volume 12 Supplement 1

Proceedings of the 21st European Pediatric Rheumatology (PReS) Congress

Open Access

High Treg development in the first year of life gives insight into immune regulation

  • Sytze De Roock1,
  • Krijn Dijkstra1,
  • Sanne Hoeks1 and
  • Berent Prakken1
Pediatric Rheumatology201412(Suppl 1):P43

https://doi.org/10.1186/1546-0096-12-S1-P43

Published: 17 September 2014

Introduction

Juvenile Idiopathic Arthritis (JIA) pathology is characterized by a disregulated adaptive immune system. This fact is exemplified by reduced regulatory T cell (Treg) functionality and increased T helper (Th)17 cell activity.

Objectives

In order to further understand the relation between Treg and Th17 development, we investigated the induction of these cells from naïve T cells in early human life.

Methods

For this, we compared cells from umbilical cord blood (CB) with cells from adult volunteers, as well as cells from schisis patients who undergo several corrective operations in early life. We cultured these cells with antiCD3 for 5 days and subsequently investigated T cell subtype induction by flow cytometry.

Results

We show that upon activation, CB cells easily adopt a Treg phenotype, whereas Th17 cells can not be induced. Although production of inflammatory cytokines is dramatically lower in CB cells, addition of Th17 inducing cytokines IL-1b or IL-6 did not influence this phenomenon. Instead, an increased programmed death (PD)-1 signaling and decreased Th17 defining transcription factor RORC activation underlie the prevention of inflammatory T cell activity. The propensity for Treg development is a phenomenon which we still observed in samples from 12 month old children, whereas we found Th17 cell development as early as three months after birth. This development in the first year of life is likely related to prevention of aberrant T cell responses towards self and the developing microbiome.

Conclusion

These data give more insight into the development of the immune system and inflammation and can lead to novel targets in JIA therapy, aiming at the balance between Treg and Th17 cells.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Laboratory of Translational Immunology, UMC UTRECHT

Copyright

© De Roock et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement